Markets SVB Leerink cuts Rubius Therapeutics to MP; TP to $4 from $19 SVB Leerink downgraded Rubius Therapeutics (NASDAQ:RUBY) to “market perform” from “outperform” and slashed its price target to $4 from $19 after the company discontinued development of RTX-134 for the treatment of... March 13, 2020